Acrivon Therapeutics Inc.’s $130 million financing disclosed April 9 hiked confidence in then-pending data with ACR-368 (prexasertib), the selective small-molecule inhibitor that targets checkpoint kinase 1 (CHK1) and CHK2. Undergoing tests in a potentially registrational phase II trial across multiple tumor types, ACR-368 also raised the stakes for Boundless Bio Inc., which is developing CHK1 inhibitor BBI-355.
Acrivon Therapeutics Inc.’s $130 million financing disclosed April 9 hiked confidence in then-pending data with ACR-368 (prexasertib), the selective small-molecule inhibitor that targets checkpoint kinase 1 (CHK1) and CHK2. Undergoing tests in a potentially registrational phase II trial across multiple tumor types, ACR-368 also raised the stakes for Boundless Bio Inc., which is developing CHK1 inhibitor BBI-355.
Alterome Therapeutics Inc. has closed a $132 million series B financing to support the advancement of its pipeline of next-generation, small-molecule targeted cancer therapies into the clinic, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor.
Context Therapeutics Inc. has submitted an IND application to the FDA to begin a first-in-human phase I study of CTIM-76 in patients with claudin 6 (CLDN6)-positive gynecologic and testicular cancers.
Claudin-6 (CLDN6) is highly expressed in several cancer types, including ovarian and endometrial cancers, while very low or no expression is found in normal tissues.
Researchers from The Second Hospital and Yuying Children’s Hospital of Wenzhou Medical University have published results of the preclinical characterization of a novel curcumin analogue, CP-41, being developed as a potential anticancer agent.
Accent Therapeutics Inc. has completed a $75 million series C financing to support progression of its lead programs through early clinical development.
Quanta Therapeutics Inc. has announced progression of its pipeline of KRAS-directed drug candidates, with the receipt of IND approval from the FDA for QTX-3034.
The Congress of the European Society of Medical Oncology (ESMO) held in Madrid from Oct. 20 to 24, 2023, could well add the letter W to its acronym after the four sessions on gynecological cancer that could represent a milestone in the lives of all women who suffer from cervical, ovarian, or endometrial cancer.
China Welfare Institute International Peace Maternity and Child Health Hospital and East China University of Science & Technology have jointly developed aza-phenothiazine derivatives reported to be useful for the treatment of endometrial cancer.
